AbbVie (ABBV.US) Q3 results beat expectations; two blockbuster new drugs contribute nearly half of revenue.

Zhitong Finance APP has learned that AbbVie (ABBV.US) reported third-quarter results that beat expectations, driven primarily by higher sales of immunology and neuroscience drugs. The company also raised its full-year profit guidance and increased its quarterly dividend by 5.2%.